Triple Therapy with Empagliflozin, Linagliptin and Gliclazide in a Patient who Refuses Insulin: New Solutions to an Old Problem

Authors:

Navarrete RET^1*, Pires WS² and Betti RT³

DOI: 10.23880/doij-16000117

Volume 1, Issue 2

Abstract

Background: Insulin therapy refusal is a common subject in the routine of endocrinologists. New therapeutic options can work around this issue.

Objective: To report a case of insulin therapy refusal in a type 2 diabetes patient and how this was handled.

Design: Interventional case report with clinical and laboratory correlation. Case Report: 54-year-old man receiving Metformin, 1.7g/d for 2 weeks. Triple oral therapy was considered after refusing insulin. Clinical evaluation and assessment of metabolic profile were completed on admission and 3 months later. The outpatient record was also reviewed.

Discussion: The triple therapy with Gliclazide, Empagliflozin and Linagliptin promoted laudable glycemic control, besides additional benefits in the blood pressure and weight loss.

Conclusion: Facing the patient’s refusal or disinterest to use insulin, new classes of oral antidiabetic drugs are required

Keywords:

DPP-4 inhibitors; SGLT2 inhibitors; Combination therapy; Type 2 diabetes

View PDF